<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055301</url>
  </required_header>
  <id_info>
    <org_study_id>S0833</org_study_id>
    <secondary_id>S0833</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT01055301</nct_id>
  </id_info>
  <brief_title>S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may&#xD;
      stimulate the immune system in different ways and stop cancer cells from growing. Drugs used&#xD;
      in chemotherapy, such as dexamethasone, cisplatin, doxorubicin hydrochloride,&#xD;
      cyclophosphamide, etoposide, and melphalan, work in different ways to stop the growth of&#xD;
      cancer cells, either by killing the cells or by stopping them from dividing. Combining&#xD;
      chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses&#xD;
      of chemotherapy drugs and kill more cancer cells. Giving bortezomib, thalidomide, and&#xD;
      combination chemotherapy before and after transplant and lenalidomide after transplant may be&#xD;
      an effective treatment for multiple myeloma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib, thalidomide, and&#xD;
      lenalidomide together with combination chemotherapy and autologous stem cell transplant works&#xD;
      in treating patients with newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess progression-free survival (PFS) at 3 years in patients with newly diagnosed&#xD;
           multiple myeloma (MM) treated with modified Total Therapy 3 (TT3).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate the frequency and severity of toxicities associated with this treatment&#xD;
           strategy in these patients.&#xD;
&#xD;
      Correlative&#xD;
&#xD;
        -  To perform gene expression profiling on CD138+ purified MM cells and unseparated bone&#xD;
           marrow biopsy samples to identify the bone marrow micro-environment signature.&#xD;
&#xD;
        -  To determine whether the 70-gene model, developed in the Arkansas Total Therapy 2 (TT2)&#xD;
           and validated in the Arkansas TT3 study, also applies to the cooperative group setting.&#xD;
&#xD;
        -  Determine whether the novel finding in TT3 of the prognostically favorable suppression&#xD;
           of a micro-environment-associated gene, MAG1, also applies to the cooperative group&#xD;
           setting.&#xD;
&#xD;
        -  Once in complete remission, determine whether the MAG signatures can return to a normal&#xD;
           individual's signature as an indication of profound tumor cytoreduction with durable&#xD;
           PFS.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive bortezomib IV on days 1, 4, 8, and 11; oral&#xD;
           thalidomide and oral dexamethasone on days 1-4; and cisplatin IV continuously,&#xD;
           doxorubicin hydrochloride IV continuously, cyclophosphamide IV continuously, and&#xD;
           etoposide IV continuously on days 1-4.&#xD;
&#xD;
        -  Peripheral blood stem cell (PBSC) collection: Beginning within 2 months after completion&#xD;
           of induction therapy, patients undergo PBSC collection until an adequate number of cells&#xD;
           are collected. Patients with persistent disease after completion of induction therapy&#xD;
           proceed to bridging therapy after adequate stem cells are collected. Patients not&#xD;
           requiring bridging therapy proceed directly to transplant.&#xD;
&#xD;
        -  Bridging therapy: Patients receive oral thalidomide on days 1-21 and oral dexamethasone&#xD;
           on days 1, 8, and 15. Treatment repeats every 21 days for 1-2 courses in the absence of&#xD;
           disease progression or unacceptable toxicity. Patients then proceed to transplant.&#xD;
&#xD;
        -  First autologous PBSC transplantation: Beginning within 6 weeks to 3 months after&#xD;
           completion of induction therapy (or ≥ 1 week after completion of bridging therapy),&#xD;
           patients receive bortezomib IV on days -4 and -1 and melphalan IV, oral thalidomide, and&#xD;
           oral dexamethasone on days -4 to -1. Patients undergo autologous PBSC transplantation on&#xD;
           day 0.&#xD;
&#xD;
        -  Inter-transplant bridging therapy: Patients with persistent disease after completion of&#xD;
           the first autologous PBSC transplant receive bridging therapy as above and then proceed&#xD;
           to the second transplant. Patients not requiring bridging therapy proceed directly to&#xD;
           the second transplant.&#xD;
&#xD;
        -  Second autologous PBSC transplantation: Beginning within 6 months after the first PBSC&#xD;
           transplant, patients receive bortezomib, melphalan, thalidomide, and dexamethasone and&#xD;
           undergo autologous PBSC as in the first transplant. Patients who skip the second&#xD;
           transplant (due to medical or insurance reasons or refusal) proceed to consolidation&#xD;
           therapy.&#xD;
&#xD;
        -  Consolidation therapy: Beginning within 6 months after the last transplant, patients&#xD;
           receive bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin hydrochloride,&#xD;
           cyclophosphamide, and etoposide as in induction therapy.&#xD;
&#xD;
        -  Post-consolidation bridging therapy: Patients with persistent disease after completion&#xD;
           of consolidation therapy receive oral thalidomide on days 1-21 and oral dexamethasone on&#xD;
           days 1, 8, and 15. Patients then proceed to maintenance therapy. Patients not requiring&#xD;
           bridging therapy proceed directly to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Beginning within 4 months after completion of consolidation therapy&#xD;
           or post-consolidation bridging therapy, patients receive bortezomib IV and oral&#xD;
           dexamethasone on days 1, 8, 15, and 22 and oral lenalidomide on days 1-20. Courses&#xD;
           repeat every 28 days for up to 3 years in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Blood and bone marrow samples may be collected at baseline and periodically during study for&#xD;
      gene expression profile analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for up to 7 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 3 years</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of toxicities</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiling analysis of CD138+ purified plasma cells</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ind (1cycle):&#xD;
bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d &amp; dex 20mg/d PO; cisplatin &amp; dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.&#xD;
PBSC Coll: at recovery per local standard&#xD;
Bridging (before/between trans/after Cons):&#xD;
thal 50mg/d D1-21 &amp; dex 20mg D1,8,15 PO&#xD;
Tandem Trans (x2):&#xD;
bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d &amp; dex 40mg/d PO PBSC &gt;/=200x10^6 cells&#xD;
Cons (1cycle):&#xD;
same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox&#xD;
Maint(&lt;/= 3 yrs):&#xD;
D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <arm_group_label>treatment</arm_group_label>
    <other_name>bort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous-autologous tandem hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed active multiple myeloma (MM)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Non-secretory disease allowed provided patient has ≥ 20% plasmacytosis or&#xD;
                  multiple (&gt; 3) focal plasmacytomas on skeletal survey and/or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status (PS) 0-2 (Zubrod PS 3-4 allowed if based solely on bone&#xD;
             pain)&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm^3*&#xD;
&#xD;
          -  Serum creatinine clearance of ≥ 60 mL/min&#xD;
&#xD;
               -  Patients with creatinine clearance of &lt; 60 mL/min receive a lower dose of&#xD;
                  melphalan&#xD;
&#xD;
               -  No patients receiving or planning to receive dialysis&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
               -  Must be fully aware of the teratogenic potential of thalidomide&#xD;
&#xD;
               -  Must be willing to comply with the FDA-mandated S.T.E.P.S. program&#xD;
&#xD;
          -  Ejection fraction &gt; 40% as measured by MUGA scan or two-dimensional ECHO&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 per CTCAE v. 4.0&#xD;
&#xD;
          -  No known hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  No uncontrolled diabetes defined as fasting glucose level &gt; 200 mg/dL on at least more&#xD;
             than two occasions or more that two serum random blood levels &gt; 300 mg/dL despite&#xD;
             adequate treatment&#xD;
&#xD;
               -  Patients with a history of diabetes mellitus requiring treatment should be on a&#xD;
                  stable regimen and have their blood glucose closely monitored&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for adequately treated basal cell&#xD;
             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the&#xD;
             patient has not received treatment within the past year NOTE: *Unless myeloma-related&#xD;
             marrow infiltration is documented, defined as ≥ 30% marrow cellularity with 50% of the&#xD;
             cells being malignant plasma cells.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No more than 1 prior course of chemotherapy for MM&#xD;
&#xD;
               -  Prior chemotherapy must not have included melphalan&#xD;
&#xD;
          -  No prior radiotherapy to large area of the pelvis (more than half of the pelvis)&#xD;
&#xD;
          -  Prior radiotherapy for symptomatic localized bone lesions or impending cord&#xD;
             compression allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muneer H. Abidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Hospital Cancer Care Center at Island Hospital</name>
      <address>
        <city>Anacortes</city>
        <state>Washington</state>
        <zip>98221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Cancer Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympic Hematology and Oncology</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highline Medical Center Cancer Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital Cancer Care Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrison Poulsbo Hematology and Onocology</name>
      <address>
        <city>Poulsbo</city>
        <state>Washington</state>
        <zip>98370</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minor and James Medical, PLLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Central Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute at Swedish Medical Center - First Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Puget Oncology at United General Hospital</name>
      <address>
        <city>Sedro-Woolley</city>
        <state>Washington</state>
        <zip>98284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Hematology and Oncology, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801-2028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

